30 January 2020 
EMA/135953/2020  
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
Medicinal product  
MabThera 
rituximab  
Pharmaceutical form(s): 
See Annex A of the CHMP Opinion 
Strength(s): 
See Annex A 
Route(s) of administration: 
See Annex A 
Packaging and package 
See Annex A 
size(s): 
Number(s)in the Community 
See Annex A 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH:  Roche Registration GmbH 
Emil-Barell-Strasse 1 
79639 Grenzach-Wyhlen 
GERMANY 
Procedure  
Procedure number: 
EMEA/H/C/000165/II/0168 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and 
in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
- the development of this product has complied with all measures in the agreed paediatric 
investigation plan P/0064/2019. All studies in the agreed paediatric investigation plan P/0064/2019 
were conducted after the entry into force of that Regulation, 
- the Summary of Product Characteristics reflects the results of studies conducted in compliance 
with this agreed paediatric investigation plan. 
In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating 
compliance with the agreed completed paediatric investigation plan P/0064/2019 is included in the 
technical dossier.  
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
 
 
 
 
  
